Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guideline-based reduction of insulin and sulfonylurea use in elderly patients with type 2 diabetes at high cardiovascular risk
NL-OMON57637Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of metformin, pioglitazone and human insulin in type 2 diabetes mellitus (T2DM), sponsored by Amsterdam University Medical Center. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
metforminpioglitazonehuman insulin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON57637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57637.